法国 84 万人用过、2801 起不良反应：欧盟第 3 次警告 GLP-1，中国出海企业必读
GLP-1（司美格鲁肽这类"降糖减重"药）有多火，不用我多说——它几乎是中国药企出海的头号赛道，国内不少公司的管线里都摆着它。
但就在 2026 年 10 月 7 日，法国药监局（ANSM）发布了第 3 份 GLP-1 药物警戒报告。这不是"批不批"的问题，而是"药已经在大范围用了，真实世界里出了什么状况"的复盘。对中国准备出海的企业来说，这份报告比任何一篇软文都值得读——因为它暴露的，恰恰是出海最容易被忽略的那道关：上市后，药是怎么被用坏的。
一、报告讲了什么（数据说话）
统计窗口是 2025 年 2 月到 2026 年 1 月，法国：
| 指标 | 数值（法国，2025.2–2026.1） |
|---|---|
| 用药者 | 超过 84 万人 |
| 不良反应报告 | 2,801 例（其中 515 例严重） |
| 滥用导致的不良反应 | 36 例（17 例严重） |
约 1/3 用于 2 型糖尿病，1/3 用于减重，其余是未填报或未获批的适应症；最常见的是胃肠道反应（恶心、呕吐、腹泻、腹痛），有时会严重到需要住院，以及已知的严重风险——胰腺炎。
更值得警惕的是滥用（mésusage）：报告了 36 例因"不当用于减重"导致的不良反应，其中 17 例严重。这些滥用者偏年轻，2/3 的药来自非官方渠道（网络、熟人、境外代购），超过 9/10 的人剂量过高或加量过快；严重案例里包含 5 例急性胰腺炎。
此外还有：营养缺乏/营养不良（再次被点名）；与窄治疗窗药物（如部分抗凝药）的相互作用需要调剂量；与二甲双胍合用在脱水时可能加重乳酸酸中毒（期间 2 例死亡疑似相关）；以及仍在监测的眼科、肝胆、脑血管等意外信号；甚至 GLP-1 可能降低避孕药效力（EMA 正在评估）。
不过要公平地说：ANSM 的结论是，在按推荐使用时，GLP-1 的获益-风险仍然是"有利"（favorable）的。报告要压的，是"滥用"和"相互作用"，不是药本身。
二、为什么这事是中国出海企业的"必修课"
很多中国老板对"出海"的理解，还停在"拿到授权、摆进展、找代理"这一步。但欧盟（和 FDA 一样）真正难的关，在上市后。
欧盟有一整套药物警戒体系：药品上市不是终点，而是被持续盯防的起点。真实世界数据一旦显示风险信号，标签（SmPC）、风险管理计划（RMP）会被动态调整，严重的甚至重启审查、撤市。GLP-1 这份报告，就是"上市后怎么管"的标准样本。
而中国药企出海 GLP-1，恰恰最容易在三个地方栽跟头——
三、三个出海启示
1. 上市后监督（PMS/PV）能力，才是护城河。 你能在欧盟卖 GLP-1，不代表你能"安全地在欧盟卖 GLP-1"。有没有本地化的药物警戒团队？能不能按欧盟要求建不良反应收集与上报通道？能不能跑得动 RMP？这些能力，比"拿到证"值钱得多。别以为授权一签就高枕无忧——GLP-1 这类"现象级"药，恰恰是监管盯得最紧的。
2. 非官方渠道流通，是颗雷。 报告里 2/3 的滥用药来自网络、熟人、境外——这不是法国独有的问题，中欧监管都想压。你的出海商业设计里，分销渠道是否可控？有没有防窜货、防非授权流通的机制？渠道失控，最后背锅的是品牌和合规信用。
3. 相互作用与特殊人群，标签要前置。 抗凝药合用、二甲双胍合用、妊娠、避孕效力——这些"边界情况"在欧盟会被写进标签和风险沟通。出海前就把这些想清楚、写进 RMP，比上市后被监管追着改，成本天差地别。
四、写在最后
欧盟这道"滥用关"，本质上考的不是你的分子有多好，而是你有没有能力让药在真实世界里被安全地用。这恰恰是中国药企从"能出海"到"出得稳"的分水岭。
France ANSM's 3rd GLP-1 Warning: A Must-Read for Chinese Firms
How hot is GLP-1 (semaglutide and similar "glucose-lowering, weight-loss" drugs)? No need to elaborate — it is almost the number-one track for Chinese pharma going global; many domestic companies have it in their pipelines.
But on 7 October 2026, France's medicines agency (ANSM) published its 3rd GLP-1 pharmacovigilance report. This is not about "approve or not" — it is a post-mortem of "the drug is already widely used, what happened in the real world". For Chinese companies preparing to go global, this report is worth more than any soft article — because what it exposes is exactly the gate most easily overlooked in going global: how the drug gets misused after launch.
1. What the report says (data speaks)
The statistics window is Feb 2025 – Jan 2026, in France:
| Metric | Value (France, 2025.2–2026.1) |
|---|---|
| Users | Over 840,000 |
| Adverse events reported | 2,801 (515 serious) |
| Misuse-related adverse events | 36 (17 serious) |
About one-third for type 2 diabetes, one-third for weight loss, the rest unreported or unapproved indications; the most common are gastrointestinal reactions (nausea, vomiting, diarrhoea, abdominal pain), sometimes serious enough to require hospitalisation, plus the known serious risk — pancreatitis.
More alarming is misuse (mésusage): 36 cases of adverse events from "improper use for weight loss", 17 serious. These misusers were younger; 2/3 of the drugs came from unofficial channels (online, acquaintances, overseas daigou), over 9/10 took too high a dose or increased too fast; serious cases included 5 acute pancreatitis.
Also: nutritional deficiency/malnutrition (flagged again); interactions with narrow-therapeutic-window drugs (e.g. some anticoagulants) require dose adjustment; combining with metformin may worsen lactic acidosis when dehydrated (2 deaths suspected related during the period); plus ocular, hepatobiliary, cerebrovascular signals still under monitoring; even GLP-1 may reduce contraceptive efficacy (EMA evaluating).
To be fair: ANSM's conclusion is that, when used as recommended, GLP-1's benefit-risk remains "favourable". What the report presses on is "misuse" and "interactions", not the drug itself.
2. Why this is a "required course" for Chinese going-global companies
Many Chinese bosses still understand "going global" as stopping at "get the licence, set up the booth, find an agent". But the truly hard gate in the EU (like the FDA) is post-marketing.
The EU has a whole pharmacovigilance system: market approval is not the end, but the start of continuous scrutiny. Once real-world data shows risk signals, the label (SmPC), risk management plan (RMP) are dynamically adjusted; serious cases even restart review or withdrawal. This GLP-1 report is a standard sample of "how to manage post-marketing".
And Chinese pharma going global with GLP-1 is most likely to trip on three points —
3. Three going-global lessons
1. Post-marketing surveillance (PMS/PV) capability is the moat. Being able to sell GLP-1 in the EU does not mean being able to "safely sell GLP-1 in the EU". Do you have a localised pharmacovigilance team? Can you build an adverse-event collection and reporting channel per EU requirements? Can you run the RMP? These capabilities are worth far more than "getting the certificate". Don't think signing the licence means smooth sailing — GLP-1, a "phenomenon-level" drug, is exactly what regulators watch most closely.
2. Circulation through unofficial channels is a landmine. 2/3 of misused drugs in the report came from online, acquaintances, overseas — not unique to France; both Chinese and European regulators want to suppress it. In your going-global commercial design, is the distribution channel controllable? Do you have anti-diversion and anti-unauthorised-circulation mechanisms? Uncontrolled channels — the brand and compliance credibility take the blame.
3. Interactions and special populations: label upfront. Anticoagulant combinations, metformin combinations, pregnancy, contraceptive efficacy — these "edge cases" get written into labels and risk communication in the EU. Think them through and write them into the RMP before launch; the cost gap vs being chased by regulators to change after launch is enormous.
4. In closing
This EU "misuse gate" essentially tests not how good your molecule is, but whether you have the capability to let the drug be used safely in the real world. This is precisely the watershed for Chinese pharma from "able to go global" to "going global steadily".